

## **SUPPLEMENTARY FIGURE LEGENDS**

Figure S1. Synergistic apoptosis induced by the combination of luteolin and EGCG. (A) Tu212 cells were treated with different doses of luteolin for 72 h and apoptosis was measured. (B) Tu212 cells were treated with different doses of EGCG for 72 h and apoptosis was measured. (C) Tu212 cells were treated with the combination of different doses of luteolin and 30  $\mu$ M EGCG for 72 h and apoptosis was measured.

Figure S2. No truncation of BID to tBID. H460 and A549 cells were treated with 15  $\mu$ M luteolin (L), 30  $\mu$ M EGCG (E) or a combination (C) of 15  $\mu$ M luteolin and 30  $\mu$ M EGCG for 72 h. Total cell lysates were immunoblotted with anti-BID that could detect both full length and truncated BID (Cell Signaling Technologies, Danvers, MA). Upper panel: short exposure; middle panel: long exposure; lower panel: actin as loading control.

Figure S3. (A) Decrease in Ki-67 expression in Tu212 xenografted tumor tissues. Representative images are shown. (B) Increase in TUNEL-positive cells in Tu212 xenograft tissues. Representative images are shown.




Figure S4. Body weight changes of mice throughout the study. Average weights of mice bearing Tu212 xenografts (A), and mice bearing A549 xenografts (B).

Figure S5: No notable organ related toxicity was found. (A) Photographs (x20) of major organs of representative mice from each group after H&E staining are shown. The liver of one mouse from the combination group that showed minimal steatosis is included in the figure. Arrow indicates steatosis. (B) Photograph of the liver of one mouse showing microabscesses as indicated by arrow.


## **SUPPLEMENTARY TABLE LEGENDS**



Table S1. Summary of pathological origin, p53 and EGFR status and expression of EFGR, p-AKT, NF- $\kappa$ B (p65) and Bcl-2 (measured by Western blotting) in the cell lines tested. Total cell lysates from normally growing cells without any treatments were used to examine the expression of the proteins.

Amin et al., Figure S1





Amin et al., Figure S2






Amin et al., Figure S4





Amin et al., Figure S5



**Amin et al., Table S1**

Cell Line	Cell type	p53 Genotype	EGFR		p-AKT	Bcl-2	NF-κB	**Sensitivity
			Genotype	level				
H292	Squamous	WT	WT	++++	+	+	++	+++++
A549	Adeno	WT	WT	+	+	+	++	++++
H460	Large cell	WT	WT	-/+	++++	++++	++	++++
H358	Adeno	Negative	WT	+	+	+	++++	+++
H322	Adeno	Mt	WT	++	+	+	+++	++
H1299	Large cell	Negative	WT	++	++	+	+++	++
Calu-1	Squamous	Mt	WT	+++	+	+++	++++	++
Tu212	Squamous	Mt	WT	++++	++++	++	+++	+++++
Tu686	Squamous	Mt	WT	++++	++++	++	+++	+++++
686LN	Squamous	Mt	WT	++++	++++	++	+++	+++++
886LN	Squamous	Negative	WT	++++	+++	+	+++	+++++

\*\* Sensitivity to the combination  
 WT-Wild-type  
 Mt-Mutant